SVB Leerink initiated coverage of Fulcrum Therapeutics (NASDAQ:FULC) with an “outperform” rating and price target of $20 in 12 months. The stock closed at $11.62 on Aug. 9. Fulcrum is a clinical-stage biopharmaceutical...
Tag - Fulcrum Therapeutics
